{"blog": [], "keywords": [{"value": "Editorials", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Conflicts of Interest", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Amphetamines", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Regulation and Deregulation of Industry", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Recalls and Bans of Products", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Fabricant, Daniel (1975- )", "name": "persons", "rank": "7", "is_major": "N"}, {"value": "Welch, Cara R (1980- )", "name": "persons", "rank": "8", "is_major": "N"}, {"value": "Dietary Supplements and Herbal Remedies", "name": "subject", "rank": "9", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2015/04/13/opinion/conflicts-of-interest-at-the-fda.html", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "contributor": "", "organization": "THE EDITORIAL BOARD"}, "type_of_material": "Editorial", "multimedia": [{"url": "images/2015/04/13/opinion/13mon2web/13mon2web-thumbWide.jpg", "legacy": {"wide": "images/2015/04/13/opinion/13mon2web/13mon2web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/04/13/opinion/13mon2web/13mon2web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/13/opinion/13mon2web/13mon2web-articleLarge.jpg", "xlargeheight": "429", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 429}, {"url": "images/2015/04/13/opinion/13mon2web/13mon2web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/04/13/opinion/13mon2web/13mon2web-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Opinion", "word_count": "533", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Industry insiders within the agency have too much say in regulating dietary supplements.", "pub_date": "2015-04-13T00:00:00Z", "news_desk": "Editorial", "headline": {"kicker": "Editorial", "print_headline": "Conflicts of Interest at the F.D.A.", "main": "Conflicts of Interest at the F.D.A.", "content_kicker": "Editorial"}, "print_page": "18", "snippet": "Industry insiders within the agency have too much say in regulating dietary supplements.", "_id": "552b6e6438f0d824bd2ecdf3", "slideshow_credits": null, "abstract": "Editorial criticizes Food and Drug Administration for its lethargic regulation of dietary supplements containing dangerous stimulant BMPEA; contends agency has been compromised by too many officials with strong ties to industry in key positions; calls on Congress to enact conflict-of-interest laws that would limit officials from acting in cases related to former employment."}